

October 27, 2022

Dear Dean Health Plan Provider:

The public health emergency has been extended through January 11, 2023. Thank you for your continued dedication and commitment to providing high-quality care to our members.

This notification contains information regarding:

- Monoclonal Antibody Treatment Member Cost Share.
- The U.S. Food and Drug Administration's (FDA) emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, Adjuvanted, for individuals 18 years of age and older.
- The FDA amended EUAs for Moderna's and Pfizer-BioNTech's bivalent vaccines to children.

Information in this notification applies to the following Dean Health Plan products: Commercial (fully insured, including ACA), Dean Administrative Services Only (ASO), WellFirst Health SSM Health Employee Health Plan ASO in Wisconsin, Medicare Advantage, and Medicaid, unless otherwise noted.

Monoclonal Antibody Treatment Member Cost Share

Effective November 1, 2022, cost-share will apply for COVID-19 monoclonal antibody treatment for members enrolled in a Dean Health Plan commercial benefit plan. Additionally, some Dean ASO plans may also opt to apply cost share for their members. Please contact the Customer Care Center at 877-234-4516 or online at deancare.com/contact-us/contact to obtain current information for a specific employer group.

The Health Plan **will continue** to waive cost-sharing for COVID-19 monoclonal antibody treatment for members enrolled in a Dean Medicare Advantage plan or the SSM Health Employee Health Plan ASO plan.

Throughout the COVID-19 pandemic, the FDA has revised authorizations for monoclonal antibody treatments as the virus has evolved. The following monoclonal antibody treatments, listed with the applicable HCPCS codes, are currently FDA authorized:

- Eli Lilly's Bebtelovimab — M0222, M0223, and Q0222
- Astra Zeneca's Tixagevimab and Cilgavimab (Evusheld) — M0220, M0221, Q0220, and Q0221
- Genentech's Tocilizumab — M0249, M0250, and Q0249

Novavax COVID-19 Vaccine

On October 19, 2022, the FDA granted EUA for the Novavax COVID-19 vaccine, Adjuvanted (NVX-CoV2373), as a first booster dose to be administered at least six months after completion of primary vaccination with an authorized or approved COVID-19 vaccine to either of the following populations:

- Individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate.

- Individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine.

The CPT code and description for administration of the Novavax COVID-19 vaccine is the following:

- **0044A** — Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; booster

Additionally, the Novavax vaccine follows a two-dose administration. The CPT codes for each dose's administration are the following:

- **0041A** — Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; **first dose**
- **0042A** — Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; **second dose**

Bivalent Vaccines to Children

On October 12, 2022, the FDA expanded the use of Moderna's and Pfizer-BioNTech's bivalent vaccines to children.

Moderna

The CPT code and description for administration of the Moderna bivalent booster for individuals 6 through 11 years is the following:

- **0144A** — Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose

Pfizer-BioNTech

The CPT code and description for administration of the Pfizer-BioNTech bivalent booster for individuals 5 through 11 years is the following:

- **0154A** — Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose

As a reminder, member cost share continues to be waived for COVID-19 vaccines and claims for vaccine administration should be submitted to the Health Plan.

Additional Health Plan Information

While the URL to our [COVID-19 provider information web page](#) has not changed, the link to the page on [deancare.com](#) has moved. To access the page from the website, hover over **For Providers** located on the top, right of the screen and click the **COVID-19 provider hub** link under Resources. Please contact your assigned Provider Network Consultant with any questions.

Sincerely,



Loretta A. Lorenzen

Vice President- Network Management & Contracting